Abliva publishes prospectus and new information contained in the prospectus
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN ABLIVA.
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the prospectus that Abliva has prepared regarding admission to trading of 74,065,306 shares on Nasdaq Stockholm as a result of the directed issue of shares resolved by the Board of Directors on 30 March 2021 with subsequent approval by the General Meeting on 29 April 2021 (the “Directed Issue”) has today been approved and registered by the Swedish Financial Supervisory Authority (“SFSA”). Due to regulatory requirements, the prospectus presents new information that has not previously been published, including information on the Company's capital structure (presented as of February 28, 2021) and a detailed presentation of the use of the proceeds from the directed issues resolved by the Board of Directors on 30 March 2021.
Prospectus
The prospectus prepared regarding admission to trading of 74,065,306 shares on Nasdaq Stockholm as a result of the Directed Issue has today, on 30 April 2021, been approved and registered by the SFSA. The prospectus can be obtained from Abliva and Erik Penser Bank and is available on Abliva's website (www.abliva.com) and on Erik Penser Bank's website (www.penser.se). The prospectus will also be available on SFSA’s website (www.fi.se).
Information regarding the use of the issue proceeds
The proceeds of 80 MSEK from both of the directed issues resolved by the Board of Directors on 30 March 2021 are planned to be used in accordance with the priority order specified below:
- costs related to Phase 1 regarding KL1333, 20 percent,
- costs related to preparations for Phase 2/3 KL1333, 60 percent,
- costs related to the development of NV354, 10 percent, and
- general business purposes, 10 percent
New financial information contained in the Prospectus
Stated in the Prospectus is Abliva's capital structure, net debt and assets as of 28 February 2021. This is due to regulatory rules which require that financial information regarding the capital structure must not be older than 90 days when the Prospectus is published. This information has not previously been published and the tables below provide this information. Note that only interest-bearing liabilities are reported in the tables. The information has not been reviewed by the Company's auditor.
Equity and liabilities as of 28 February 2021
| kSEK | 2021-02-28 | Adjustments³ | Adjustments for the directed issues |
| Current interest-bearing liabilities | |||
| With guarantee | - | - | - |
| With collateral¹ | 211 | - | 211 |
| Unsecured credit | - | - | - |
| Total current interest-bearing liabilities | 211 | - | 211 |
| Long term interest-bearing liabilities | |||
| With guarantee | - | - | - |
| With collateral¹ | 90 | - | 90 |
| Unsecured credit | - | - | - |
| Total long-term interest-bearing liabilities | 90 | - | 90 |
| Equity² | |||
| Share capital | 14,817 | 5,333 | 20,150 |
| Other capital contribution | 660,025 | 74,667 | 734,692 |
| Reserves | 616 | - | 616 |
| Retained earnings including profit for the year | -535,096 | - | -535,096 |
| Total equity | 140,362 | 80,000 | 220,362 |
| Total equity and interest-bearing liabilities | 140,663 | 80,000 | 220,663 |
¹ Refers to leasing liability right of use.
² As of 31 December 2020.
³ Adjustments due to the directed issues the directed issues resolved by the Board of Directors on 30 March 2021.
Net debt as of 28 February 2021
| kSEK | 2021-02-28 | Adjustments² | Adjustments for the directed issues |
| A. Cash and cash equivalents | - | - | - |
| B. Other cash and liquid assets¹ | 52,954 | 80,000 | 132,954 |
| C. Easily realisable securities | - | - | - |
| D. Total liquidity (A+B+C) | 52,954 | 80,000 | 132,954 |
| E. Current receivables | - | - | - |
| F. Current liabilities to credit institutions | - | - | - |
| G. Current portion of long-term liabilities | 211 | - | 211 |
| H. Other current interest-bearing liabilities | - | - | - |
| I. Total current interest-bearing liabilities (F+G+H) | 211 | - | 211 |
| J. Net current interest-bearing liabilities (I-E-D)² | -52,743 | -80,000 | -132,743 |
| K. Long-term liabilities to credit institutions | - | - | - |
| L. Issued bonds | - | - | - |
| M. Other long-term interest-bearing liabilities | 90 | - | 90 |
| N. Total long-term interest-bearing liabilities (K+L+M) | 90 | - | 90 |
| O. Net debt (J+N) | -52,653 | -80,000 | -132,653 |
¹ Consists of available liquid assets on a bank account.
² Adjustments due to the Directed Issue
Advisors
Erik Penser Bank AB is financial advisor and Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Directed Issue.